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Abstract: Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive   malignant 
glioma and the most frequent primary tumor of the central nervous system. The median 
  survival of newly diagnosed GBM patients was between 9 to 12 months prior to treatment with 
  temozolomide being introduced. Primary resection that is as complete as possible is recom-
mended for malignant glioma. Conventional fractionated irradiation 55 to 60 gy with concomi-
tant temozolomide followed by standard temozolomide 6 cycles (5/28) (EORTC/NCIC-regime 
published by R Stupp in 2005) is the standard of care for newly diagnosed GBM after surgery, 
independent of the methylation status of the MGM-T gene promoter. Age is no   contraindication 
for treatment with temozolomide, although comorbidity and performance status have to be 
  considered. For temozolomide naive GBM and astrocytoma grade III patients with disease 
progression, temozolomide is still the treatment of choice outside of clinical studies. A   general 
consensus regarding the schedule of choice has not yet been achieved; so far the 5 out of 
28 days regimen (5/28) is the standard of care in most countries. Patients with disease progression 
after standard temozolomide (5/28) are candidates for clinical studies. Outside of clinical   studies, 
dose-dense (7/7), prolonged (21/28), or metronomic (28/28) temozolomide, or alternatively a 
nitrosourea-based regimen can be an option. The excellent toxicity profile of   temozolomide 
allows for various combinations with antitumor agents. None of these   combinations, however, 
have been demonstrated to be statistically significantly superior compared to temozolomide alone. 
The role of lower dosed, dose-dense, or continuous regimen with or without drug combination 
and the role of temozolomide for newly diagnosed astrocytoma grade III and low grade glioma 
still has to be determined.
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Primary tumors of the central nervous system are classified according to the World 
Health Organization (WHO) guidelines, which were updated in 2007.1 Glioblastoma 
multiforme WHO grade IV (GBM) is one of the most aggressive human malignant 
diseases and the most frequent primary tumor of the central nervous system with an 
incidence of 4–5 per 100,000 inhabitants per year in industrialized countries like Europe 
and the US. The median survival of newly diagnosed GBM patients ranged from 9 to 
12 months prior to the introduction of treatment with temozolomide. About two thirds 
of all GBM cases arise as a primary tumor while one third   develops as secondary GBM 
on basis of prior lower grade malignancies like astrocytoma grade III which shows 
clear malignant criteria in histopathology and astrocytoma grade II without clear 
malignant criteria.2 For confident histopathological diagnosis a   representative specimen OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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of the tumor has to be analyzed, and reference pathology is 
recommended if diagnosis is not clear. Specimens obtained 
by stereotactical puncture might not be representative of 
the entire tumor and should be considred to be an excep-
tion. Oligodendroglioma grade III is a well defined subtype 
of astrocytoma grade III and shows better sensitivity to 
  chemotherapy, resulting in an improved median survival. 
These tumors more often show loss of heterogeneity of 
chromosome 1p and 19q (LOH 1p19q), which is predictive 
of a better response to alkylating drugs.3,4
Abnormal interactions between macroglia, microglia, a 
special type of immune competent intracerebral migrating 
and modulating cells and the microvascular structure appear 
to play a role in the development of primary brain tumors.5
It has been demonstrated that many growth factor receptor 
families, such as epithelial growth factor receptor (EGF-R), 
platelet derived growth factor receptor (PDGF-R), and 
  vascular endothelium growth factor receptor (VEGF-R), and 
their mutations, are involved in pathogenesis of GBM.6–12 
There is evidence that primary and secondary GBM have 
a different molecular-genetic basis, however, treatment has 
not been stratified by these findings so far.2,13–15
The methylation status of the O6-methylguanin-
methyltransferases (MGM-T) gene promoter is important 
for upcoming trials and potentially for future treatment 
  strategies. MGM-T is a genome repair enzyme able to repair 
DNA lesions caused by alkylating drugs. In about 50% of 
GBM the MGM-T gene promoter is methylated, resulting 
in silencing of the gene and lack of MGM-T capacity with 
an increased sensitivity to alkylating drugs compared to 
GBM with   nonmethylated MGM-T promoter and normal 
MGM-T level.16 This explains why patients presenting a 
GBM with a methylated MGM-T promoter respond better 
to chemotherapeutic agents and have a prolonged survival. 
Neurooncologists all over the world have discussed the impact 
of methylation of the MGM-T promoter on individualization 
of treatment,   however, consensus recommendations are still 
missing.17 There is evidence in the literature that prolonged 
or continuous treatment with alkylating drugs could subse-
quently deplete MGM-T activity.18,19
Treatment of glioblastoma 
multiforme in the pre-
temozolomide era
The first treatment step after detection of an intracerebral 
tumor which provokes suspicion of a central nervous tumor 
is neurosurgical resection that is as complete as possible. 
Many researchers have indicated that the extent of resection 
is of prognostic value.20 Patients with complete macroscopic 
resection show a prolonged survival. Preoperative infu-
sion of delta-aminolevolinic acid (ALA) marks malignant 
  tissue in fluorescing light which is useful for determining 
the   optimal resection margin intraoperatively. Another tech-
nique to improve extent of resection and to avoid neurological 
  deficits is the so called “awake resection”.21 A combination 
of ALA-technique and awake-resection is possible and seems 
to improve surgical approach in selected patients. Although 
resection techniques have improved it has become evident 
that even complete resection cannot cure a GBM patient 
due to disseminated malignant cells surrounding the detect-
able tumor being able to migrate along the intracerebral tracks 
and cords. Therefore median survival after resection alone 
remains at less than 12 months, indicating the clear need for 
additional treatment options to be developed.
In relation to this, it has been demonstrated that   conventional 
fractionated radiotherapy with an equivalent dose of 54 to 60 gy 
was able to prolong survival for a median of 3 months, resulting 
in a median overall survival of 12 months for GBM patients. 
Nearly all resected and   irradiated GBM patients experience a 
local or distant progression within the central nervous   system 
within 9 months after first surgery, however, metastases 
  outside the central nervous system are rare (less than 1%). 
In the case of relapse, resurgery and/or reirradiation may be 
offered to the patient followed or replaced by local or systemic 
chemotherapy based on nitrosoureas such as lomustin, 
carmustine, or nimustine, or on topoisomerase inhibitors such 
as teniposide or etoposide.22–27 In the US treatment with irino-
tecan (CPT-11) is an option in this situation.28 Interestingly, 
only drugs administered in vivo are able to penetrate the intact 
blood–brain barrier and therefore show activity in primary 
brain tumors.
All of these local and systemic chemotherapeutic options 
achieved objective response rates of between 0 and 15%, 
with a median survival benefit of less than 3 months.   Overall 
survival therefore was nearly unchanged at a median of 
approximately 12 months. Good performance status and 
younger age were predictive for better response.29
The administration of nitrosoureas after completion of 
  irradiation without progression, called “adjuvant” by many 
authors, demonstrated a modest but consistent improvement of 
overall survival with the 2-year survival rate increasing from 
15% to 20%.30,31,27 Treatment was given for 6 cycles spaced over 
6 months. Continuation of the treatment until progression in the 
sense of a real maintenance treatment was not examined.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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The low long-term survival prognosis of GBM made 
further investigation of new drugs necessary. Between 1990 
and 2000 the most promising drug under investigation in 
progressive GBM was temozolomide, an oral alkylating drug 
with a moderate toxicity profile able to penetrate the intact 
blood-brain barrier.
Development of temozolomide 
for glioblastoma multiforme
Temozolomide was initially developed with the intent to 
treat patients with metastases to the brain for   malignant 
melanoma  but  it  also  showed  activity  in  relapsed 
GBM patients,   encouraging further investigation.32–34 
  Temozolomide is characterized by rapid, nearly complete 
oral absorption. It converts spontaneously into MTIC 
(5-(3-methyltriazen-1-yl)imidazol-4-carboxamid), and the 
active metabolite shows a plasma peak   concentration within 
30 to 90 minutes after uptake, with a plasma half time of 
2 hours.35 The cytotoxic activity of   temozolomide is explained 
by O6-methylation of the guanine. O6-methylguanine 
is mutagenic and able to trigger apoptosis. MGM-T, a 
  DNA-repair enzyme, is involved in removing temozolomide-
induced methyl adducts at the same time as it depletes the 
metabolic capacity of this enzyme.16,36,37 Temozolomide was 
first investigated in an oral 5 day regimen with 250 mg/m² 
administered daily, repeated every 4 weeks for 6 cycles. 
Toxicity was moderate even though a more favorable toxicity 
profile could be demonstrated for continuous oral treatment 
at a dosage between 75 and 85 mg/m² of the body surface. 
With the exception of an increased risk for pneumocystis 
carinii pneumonia, antibiotic prophylaxis is recommended 
in regimens with more than 100 mg daily continuous dosage. 
There is no documented influence of steroids or enzyme-
inducing antiepileptic drugs on efficacy of temozolomide.
The situation of relapse
Yung et al were the first to report the statistically significant 
superiority of a monotherapy regimen of temozolomide com-
pared to procarbazine at first relapse in patients with GBM 
and anaplastic astocytoma WHO grade III using a regimen of 
200 to 250 mg temozolomide/m² body surface orally before 
breakfast on days 1 to 5 of a 28 days cycle.38,39 The objec-
tive response rate was about 30% with a moderate toxicity 
profile; nausea or vomiting usually was only present on 
days 1 to 3 of the 5 days of drug incorporation. It was found 
that 5-HT-3 antagonists were required in some cases, and 
additionally, grade III and IV hematotoxicity rates were low, 
with about 15% of patients affected, and treatment-related 
  myelodysplasia or acute myeloid leucemia being very rare 
events.40 The progression-free survival rate at 6 months was 
about 40%. The results of Yung et al study were confirmed by 
other researchers, which led to replacement of nitrosoureas 
and topoisomerase inhibitor-based regimens for patients with 
GBM and anaplastic astrocytoma in first relapse.41 Temozo-
lomide conventionally dosed with 200 mg/m² body surface 
on days 1 to 5 of a 28 day cycle became the most commonly 
used regimen for GBM and anaplastic astrocytoma patients at 
first relapse around the world. However, the optimal duration 
of treatment remains unclear. Some researchers recommend 
treatment until progression or intolerable toxicity occurs, 
but the majority of researchers tend to restrict treatment to 
a maximum of 6 cycles. The standard follow up for these 
patients includes an MRI scan of the brain every 3 months, 
however in the last 2 years more and more neurooncologists 
have been recommending MRI scans every 8 weeks.
In case of relapse after standard dosed temozolomide 
(5/28) treatment, options are limited. While nitrosourea-
based regimens have not shown promising activity in 
this situation, with objective response rates of less than 
5%, many   researchers have investigated different   dose- 
and time-modified temozolomide schedules after standard 
dosed temozolomide has been administered.42–47 Supported 
by the assumption that continuous treatment with   alkylating 
drugs like temozolomide induces depletion of MGM-T 
activity, the favorable toxicity profile of temozolomide 
led to the   development of dose-dense, prolonged, and 
metronomic temozolomide schedules, all of which show-
ing moderate activity when administered after standard 
temozolomide.48,49
The dose-dense or one week on/one week off regimen 
with temozolomide 150 mg/m² body surface on days 1 to 7, 
repeated on day 15 (7/14) seems to be the most effective regi-
men, with a 48% progression-free survival rate at 6 months 
(PFS6).50,51 The prolonged regimen with 75 to 100 mg/m² 
body surface on days 1 to 21, repeated at day 29 (21/28), 
showed a PFS6 of 30%. The metronomic regimen with 
daily temozolomide 50 mg/m² body surface on days 1 to 28, 
repeated on day 29 (28/28), demonstrated a PFS6 of 35%.52 
Dose- and/or time-intensified temozolomide regimens cause 
an increased grade III and IV hematotoxicity of 20% to 40%, 
with an increased risk of pneumocystis carinii pneumonia and 
herpes virus infections varying from 0% to 2%. Antibiotic 
and antiviral prophylaxis should be considered in these cases. 
While many neurooncologists seem to prefer dose-dense OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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or prolonged temozolomide regimens, there is no proof of 
the significant superiority of one of these regimens over the 
standard 5/28 temozolomide so far.
Although standard dosed and dose- and/or time-modified 
regimens of temozolomide have been found to significantly 
improve outcome of patients with malignant gliomas, the 
prognosis of these patients remains unsatisfactory.
Primary treatment situation
eORTC/NCiC-protocol
Wedge and van Rijn collected preclinical data which led to 
them suggesting a synergistic effect of temozolomide and 
irradiation therapy. Stupp et al demonstrated the feasibility 
of concomitant temozolomide and irradiation therapy in 
newly diagnosed GBM patients.53,54 The data encouraged 
Stupp to initiate a randomized phase III study for newly 
diagnosed GBM patients in cooperation with the EORTC 
and the NCIC.55,56 Stupp and colleagues compared irradiation 
therapy with concomitant temozolomide followed by 6 cycles 
of standard dose temozolomide (5/28) versus irradiation 
therapy alone. This research became a landmark study for 
the treatment of newly diagnosed GBM patients.
Concomitant temozolomide was dosed at 75 mg/m² body 
surface each day, including weekends, during irradiation 
followed by 6 cycles temozolomide 200 mg/m² on days 
1 to 5, repeated on day 29 (5/28-regimen). Patients received 
conventionally fractionated irradiation in both arms with a 
total dose of 55 to 60 gy.
The toxicity of temozolomide was moderate with 
grade III and IV hematotoxicity of 7% in the concomitant 
phase and 14% in the standard dose phase.
Radiotherapy plus temozolomide was statistically sig-
nificantly superior to radiotherapy alone according to all 
endpoints, with a consistent difference reported over time. 
This became the new treatment standard for newly diagnosed 
GBM patients.
The addition of temozolomide improved patients’ 
median survival (15.6 months versus 12.1 months), 2 year 
overall survival (27.2% versus 10.9%), 3 year overall 
survival (16.0% versus 4.4%), and 5 year overall survival 
(9.8% versus 1.9%). The superiority of the temozolomide 
arm continuously improved over time.57 In a correlational 
study on health-related quality of life no negative impact of 
concomitant temozolomide was found. Additional analysis 
of the data confirmed good performance status and younger 
age as predictors for better response to treatment.
Methylation status according to MGM-T gene promoter 
demonstrated the best results for patients with methylated 
MGM-T gene promoter in both treatment arms, as expected, 
with combined median overall survival in the entire study 
population of 18.2 years for methylated MGM-T promoter 
versus 12.2 years for unmethylated MGM-T promoter. 
According to the treatment arms, the differences became more 
impressive. Patients with methylated MGM-T promoter had 
a median survival rate of 21.7 months with combined treat-
ment versus 15.3 months with radiotherapy alone. The 2 year 
survival rates were 46% versus 22.7% respectively, while 
patients with unmethylated MGM-T promoter had a median 
survival of 12.7 months with combined treatment   versus 
11.8 months with radiotherapy alone, and 2 years survival 
rates were 13.8% versus ,2% respectively.58,48 As expected, 
the data indicate that patients with methylated MGM-T gene 
promoters clearly benefit more from temozolomide but even 
patients with unmethylated MGM-T gene promoters benefit 
from temozolomide, especially with long-term survival being 
possible only in the combined treatment arm.
In the temozolomide era MGM-T gene promoter status 
again is a clear prognostic factor but still does not have an 
impact on individualization of treatment. Although there are 
arguments for the use of a prolonged temozolomide regimen 
for unmethylated MGM-T gene promoter status, there is no 
consensus about this overall in the literature.
In a recently published randomized phase II study 
  irradiation plus concomitant temozolomide followed by either 
dose-dense or metronomic temozolomide was compared in 
newly diagnosed GBM patients. Toxicity was moderate in 
both arms but there was no evidence of the superiority of 
one of the tested arms compared to the historical data of 
the original EORTC-protocol so far. In this study the prog-
nosis of patients with unmethylated MGM-T gene promoter 
was better than expected, however the number of patients was 
too small to reach statistical significance. Further investiga-
tion of prolonged temozolomide regimen for patients with 
unmethylated MGM-T promoter is recommended.59
There is evidence in the literature that elderly patients sub-
stantially benefit from treatment with temozolomide and despite 
the side effects, especially an increased rate of neutropenia and 
thrombocytopenia temozolomide, it should be offered to elderly 
patients with good performance status as well, especially in the 
form of a lower dosed continuous regimen.60–63
Temozolomide regimen
1.	 Standard (5/28):
  150 to 200 mg/m² on days 1 to 5, repeated on day 29.
2.	 Dose-dense (7/7):
  150 mg/m² on days 1 to 7, repeated on day 8.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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3.  Prolonged (21/28):
  75 to 100 mg/m² on days 1 to 21, repeated on day 29.
4.  Metronomic (28/28):
  50 mg/m² continuously on days 1 to 28, repeated day 29.
5.  Concomitant to irradiation (days 1 to 42/49):
  75 mg/m² per day for 42 to 49 days during irradiation 
period.
Further developments and 
questions
A. Best temozolomide schedule
Which temozolomide regimen is the optimal treatment option 
in which situation remains an unanswered question. Different 
researchers promote dose-dense, prolonged, or even continu-
ous strategies, especially in case of unmethylated MGM-T 
promoter status, so an overall consensus regarding which 
treatment is recommended has not yet been reached.64
B. eORTC/NCiC regimen for newly 
diagnosed astrocytoma wHO grade iii
Many neurooncologists recommend the EORTC/NCIC 
regimen for newly diagnosed astrocytoma WHO grade III 
analogue to GBM. Histopathology and clinical characteristics 
of astrocytoma WHO grade III seem to support this strategy. 
As phase III studies do not include analyses of treatment of 
newly diagnosed astrocytoma WHO grade III with temozo-
lomide, these are not included in the current research.
C. Combination regimen
The excellent toxicity profile of temozolomide allows for 
various combinations with antitumor agents. Many stud-
ies have been carried out with the purpose of investigating 
combination therapy of temozolomide with other chemo-
therapeutic drugs, monoclonal antibodies, and thyrosine 
kinase inhibitors. None of these combinations, however, have 
demonstrated statistically significant superiority compared to 
temozolomide alone. Research must therefore be continued 
in this area.
Combinations under investigation
These combinations are under investigation in the first line 
and relapsed situation (list incomplete):
Temozolomide plus
A.	Chemotherapy65–70
-	 CCNU
-	 Cisplatnum
-	 Hydroxyurea
-	 Pegylated liposomal Doxorubicin
-	 Procarbacin
-	 Etoposid
-	 Topotican
-	 Paclitaxel
-	 Fotemustine
-	 Topic BCNU (wafer)
B.	 Thyrosinekinase-inhibitors (TKI)71–73
-	 Erlotinib
-	 Gefitinib
-	 Cediranib
-	 Cilengitide
-	 Sunitinib
-	 Lapatinib
C.	Monoclonal antibodies1
-	 Bevacizumab
-	 Cetuximab
-	 Panitumumab
D.	Further antitumor/metabolic agents74–76
-	 Tamoxifen
-	 Thalidomide
-	 Celecoxib
Compared to temozolomide monotherapy, there is cur-
rently no evidence that combination with the investigated 
drugs might be superior. Therefore none of the combination 
regimens have reached admission status so far.
Summary
The EORTC/NCIC-regime published by R Stupp in 2005 still 
is the standard of care for newly diagnosed GBM patients, 
independent of the methylation status of the MGM-T gene 
promoter. Age is not a contraindication for treatment with 
temozolomide, although co-morbidity and performance 
status have to be considered. Many new treatment options 
including targeted therapies are evolving and will sooner or 
later optimize the treatment for patients with malignant brain 
tumors. For temozolomide-naive GBM and astrocytoma 
grade III patients with disease progression, temozolomide 
is still the treatment of choice outside of clinical studies. 
An overall consensus on a recommendation for the sched-
ule of choice has not yet been achieved, although so far the 
5 out of 28 days regimen (5/28) is the standard of care in 
most countries.
Patients with disease progression after standard 
  temozolomide (5/28) are candidates for clinical   studies. 
  Outside of clinical studies dose-dense (7/7), prolonged 
(21/28), or metronomic (28/28) temozolomide, or   alternatively OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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nitrosourea-based regimens can be an option. Individualized 
treatment options including resurgery, reirradiation, or a 
combination of drugs should be discussed with the patient 
based on individual characteristics and relevant literature.
As long as potentially effective treatment alternatives are 
available, 6-weekly (or 8 at the most) MRI scans are recom-
mended to detect tumor progression in time to be able to 
change treatment before deterioration of performance status 
makes further treatment impossible.
Well designed fast track studies (endpoint PFS6 or 
shorter, ie, PFS3) are needed to identify treatment   strategies 
with real treatment potential within the growing offer of 
old, new, and up-coming drugs and their combinations. 
These studies should be followed by slow track studies (end-
point PFS12 or survival) to define the role of these strategies 
within the established treatment options.
Although patent protection of temozolomide ran out in 
2009 investigation of temozolomide as a substantial part of 
the treatment of malignant brain tumors should be continued. 
In particular, the role of lower dosed continuous regimen with 
or without drug combinations and the role of temozolomide 
for newly diagnosed astrocytoma grade III and low grade 
glioma needs to be determined.
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